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3Abstract
The purpose o f  this research is to study the effect o f  an increase in prescription 
drug copaym ents on utilization and associated costs. Using a cross-sectional, time series, 
cohort study design consisting o f  2,389 members continuously enrolled for 24 months, 
from one large em ployer enrolled in a M idwest HMO, this study com pares 1998 
prescription drug costs and utilization when there was a $0 copay, to 1999 costs and 
utilization after a $5 copay was implemented.
Using the difference-of-m eans test, em pirical results indicate that:
1) Drug utilization (measured by prescription claims PM PY) declined from 1998 to 
1999 but the decline was not statistically significant.
2) Total drug costs PM PY hcreased significantly (at the 1% level) from 1998 to 
1999 because o f  an increased use o f  brand over generic drugs, which led to a 
statistically significant increase in ingredient cost.
3) However, overall drug costs to the HMO showed a statistically significant 
decrease o f  1.6% from 1998 to 1999 for three reasons:
a) The $5 copayment was introduced in 1999.
b) There was a statistically significant decrease in fill fee PM PY to the HMO 
from 1998 to 1999.
c) There was a statistically significant increase in the add-in-fee PM PY from 
1998 to 1999.
These three factors all contributed to the statistically significant reduction in prescription 
drug costs to the HMO from 1998 to 1999.
Therefore, this study shows that an increase in a prescription drug copaym ent can 
provide substantial savings to both employers and HMOs without becom ing a deterrent to 
overall utilization.
5Introduction: The Problem
W ith an em ployer-based health care system and restricted corporate budgets, 
rising health care costs could spell the end o f the prescription drug benefit for many 
A m ericans. Pharm aceutical costs have risen sharply as advances in technology and the 
dem ands o f  an aging population spur the creation and consumption o f  expensive new 
drugs. I f  we expect to enjoy continuing prescription drug coverage through our 
employers, we m ust find ways to control expenses and limit the excessive use o f 
prescription drugs. Figure l 1 shows the trend o f  prescription drug expenditures by payer 
from 1990-1998, as well as the dramatic shift from out-of-pocket expense to private 
insurance.
As the population continues to age, we will consume more, and spend more, on 
prescription drugs (figure 2). Since m anaged care organizations dominate the health care 
landscape and advocate more aggressive treatm ent o f  disease states, recom m ended 
treatm ent guidelines will certainly add to the num ber o f  prescriptions written. M ost 
significant, perhaps, is that the average human life span has increased from 47 years at 
the turn o f  the century, to 62 years in 1935 and to 75 years today. W om en who are free 
o f  heart disease and cancer at the age o f 50 are now predicted to reach an average age o f 
92 years. In addition, 10 m illion baby boom ers will reach the age o f  90, one m illion o f 
them  becom ing centenarians (K ongstvedt, 2001). How will we pay for the costly new 
drugs that continue to receive FDA approval each year? How are prescription drug costs 
and utilization affecting our society?
1 A ll v isu a ls can be found on the su cceed in g  page
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8N ew  science creates new drugs. This, in turn, gives people new  treatm ent options. 
Individuals w ho w ere previously untreated or under-treated now  have the ability to 
receive treatm ent. N ew  science creates the basis for more patients entering treatm ent 
because the rates o f  diagnosis and awareness o f  disease have increased. It is im portant to 
note, as survival tim es lengthen, that the num ber o f  patients under treatm ent w ill grow, 
and the num ber o f  prescriptions w ritten w ill also continue to grow  (Dubois, Chawla, 
N eslusan, Smith, & W ade, 2000).
To dem onstrate the im portance o f  the role new  drugs play in the dram atic increase 
in prescription drug utilization, drugs introduced since 1992 accounted for over 40%  o f 
prescription drug costs and over 25% o f prescription drug utilization in 1999. According 
to K leinke (2000), “Pharm aceutical com panies believe that having m ore patients using 
newer, better drugs serves to offset other m edical costs in excess o f  the incremental 
pharm acy costs” (p. 80). The introduction o f  new drugs will continue to increase over the 
next five years—increasing utilization and costs. Figure 3 shows the average annual 
num ber o f  new  drugs approved by the FDA from 1990-1998. In addition to the increased 
num ber o f  new  prescription drugs com ing to the m arket, the FDA is approving 
prescription drugs at a faster rate each year (figure 4).
In 1997, the FD A  issued a draft proposal for new guidelines on direct-to- 
consum er (DTC) advertising. For the first time, m anufactures w ere allowed to provide 
both the d rug’s nam e and the condition it treats w ithout disclosing all o f  the product’s 
risks (W ilkes, Bell, & Kravitz, 2000). As figure 5 dem onstrates, the num ber o f 
prescriptions w ritten in 1998 (the year after the new  FD A  guidelines) increased from 2.4 
billion in 1997 to 2.6 billion in 1998, an 8.3% increase. This is im portant inform ation
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since the rate o f  prescriptions written was already rising steadily at a rate o f 
approxim ately 5% and after the new legislation, the rate jum ped to over 8% which 
represents a 60%  increase in year over year growth. Consequently, spending on direct-to- 
consum er advertising has increased from $55 m illion in 1991 to $1.3 billion in 1998 and 
alm ost $2 billion in 1999. (See figure 6). A ccording to W oloshin, Schwartz, Trem mel & 
W elch, (2001):
M any pharm aceutical com panies have reduced the am ount spent on direct- 
to-physician advertising, which suggests a tactical switch in their focus 
from physicians to patients. In 2000, drug com panies spent more on 
advertisem ents in new spapers and popular m agazines than they did in 
m edical journals ($685 m illion versus $473 m illion respectively)
(P-1141).
These ads serve to increase consum er curiosity, leading to patient requests and dem ands 
or an increase in dem ands for prescriptions. D irect advertising by pharm aceutical 
com panies clearly correlates w ith an increase in the dem and for prescription drugs. The 
question is w hether these additional prescriptions are appropriate (W ilkes et ah, 2000). A 
num ber o f  experts (Dubois, Chawla, N eslusan, Smith & W ade, 2000) conclude that, 
through direct advertising to consumers, patient requests have becom e an increasingly 
com m on lever used by the pharm aceutical industry as it seeks to extend profits and delay 
introduction o f  generically equivalent products. W oloshin et al., (2001) believe, 
“Pharm aceutical com panies are able to accom plish this by encouraging consumers to 
believe that a problem  m ight exist (where they previously w ould not) and that a 
pharm acological solution is the appropriate w ay to deal w ith it” (p. 1145).
D irect-to-consum er advertising w ill also enter cyberspace. As Findlay (2001) 
reported,
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Healthcare web sites are already supported in part by prescription drug 
advertising, although com panies spent less than $1 million on such 
prom otion in 1999. That figure will probably grow as the Internet 
becom es even m ore popular and advertising in general on the Internet 
finds a m ore solid niche. The critical policy question posed by the growth 
in direct-to-consum er advertising is whether, over time, the benefits o f 
raising consum er awareness o f  specific (mostly new) prescription drugs 
and the conditions the medicines treat will outweigh the danger that 
consum ers w ill begin to dem and and use some m edicines inappropriately 
( p l  17).
In addition to traditional advertising, the new cyberspace advertising m arketplace will 
only add to the am ount o f  m oney that pharmaceutical com panies spend to prom ote their 
products.
In an attem pt to control prescription drug spending, cost sharing for prescription 
pharm aceuticals is now com mon in all three major m arkets— public entitlem ent program s 
(M edicaid), private insurance, and managed care (Levy, 1992). Two widely used cost 
sharing strategies have emerged: instituting employee copayments, and encouraging the 
use o f  generic substitutes through differential copayments (Smith, 1993). There are three 
form s o f  cost sharing: coinsurance, deductibles, and copayments. Coinsurance represents 
a provision in a m em ber’s coverage that limits the am ount o f  coverage by the plan to a 
certain percentage, com m only 80%. A deductible represents that portion o f  a m em ber’s 
health care expenses that m ust be paid out-of-pocket before any insurance coverage 
applies (K ongstvedt, 2001). Copaym ent can be defined as a small fixed charge that is 
paid by the beneficiary for each unit o f  service consumed (Reeder & Nelson, 1985).
15
Prescription Drug Cost Sharing
Cost sharing for prescription drugs has several objectives. One such objective is
to pass som e o f  the cost o f  the prescription onto the consum er. This helps reduce
em ployer paym ent responsibility and forces the consum er to realize some level o f
econom ic responsibility. A nother objective is to reduce utilization o f  prescription drugs
by deterring individuals from unnecessary or m arginal use o f  non-essential medications.
C opaym ents are also presum ed to inject an elem ent o f responsibility back into the drug
m arketplace. M aking the consum er conscious o f  costs m ay lead to com petition and
low er-cost sources (generic drugs) (David, 1994). The purpose o f  any type o f  cost
sharing provision is to cause the individual to realize the cost associated with the service
and to take som e econom ic responsibility. M otheral and H enderson (1999b) reported,
A ccording to econom ic theory, if  individuals are required to pay a portion 
o f  the prescription costs, they w ill use prescriptions m ore prudently and 
w ill evaluate the need for the m edication and also the availability o f  a less- 
expensive substitute (generic). A ccordingly, the num ber o f  prescriptions 
should fall as the price increases, if  other factors are unchanged. This 
assertion is based on G rossm an’s derived dem and m odel for m edical care.
(p. 1384).
The question than becom es, “Is the copaym ent large enough to cause the consum er to 
debate the m erits o f  the m edication but not too large as to deter utilization o f  “ essential” 
drugs?” A ny free product is bound to be abused since individuals are not punished for 
m isuse, overuse or abuse o f  the product. In this instance, the “punishm ent” is economic.
To balance the dem ands for access to pharm aceuticals w ith pressures to constrain 
costs, levels o f  cost sharing m ust be set in a m anner that achieves appropriate clinical and 
financial outcom es (Fendrick, Smith, Chem ew , & Shah, 2001). This balance raises 
several im portant questions. W hat are the potential adverse affects o f  copaym ents for
16
prescription drugs in an indigent population (Reeder & Nelson, 1985)? W ill a copaym ent 
create a barrier that prevents an individual from getting a prescription filled, and therefore 
cause a negative health outcom e? Is health status negatively affected by cost sharing? If  
so, excessive cost sharing measures can reduce prescription drug utilization but raise 
other health care costs such as em ergency room and inpatient hospitalization. Cost 
sharing, w hile initially designed to control over-utilization, may also influence the 
decision to initiate care (Reeder & Nelson, 1985). In some portions o f the M edicaid and 
M edicare populations, it is an econom ic reality that the cost to fill a prescription m ay 
interfere w ith other essential life activities such as the ability to purchase food. How does 
one decide between eating and taking medicine? How does cost sharing affect utilization 
for “essential” and “non-essential” prescription drugs? These are all questions that, 
w hen answered, will help us understand both the benefits and limitations o f  prescription 
cost sharing. Does the value that a particular drug provides, in relation to other goods or 
services that are perceived as being necessary to the individual, affect w hether the 
prescribed drug is purchased?
17
Key Question
W hat effects do prescription drug copaym ents have on utilization and associated 
overall costs in the general population (non-M edicare and non-M edicaid enrollees)?
Review of the Literature
Several studies have exam ined the effects o f  prescription drug copaym ents on 
utilization. The first was the RAND Health Insurance Experiment (HIE), which 
investigated alternative forms o f  healthcare financing through a random ized trial 
spanning nearly a decade and involving 7,700 insured individuals across the U.S. Study 
participants w ere random ly assigned to insurance plans with varying copayment, 
deductible and m aximum expenditure levels (Reeder et al., 1993). The purpose o f  the 
study w as to determ ine the effects o f  cost sharing on the utilization o f  m edical services 
and expenditures (N ew house et al., 1981). Results o f  the RAND study indicated that, 
“individuals w ith m ore generous insurance buy m ore prescription drugs” (Leibowitz, 
M anning, & N ew house, 1985, p. 1063).
U sing RAND (HIE) data, Leibow itz, M anning and N ew house (1985), were able 
to estimate how cost-sharing affects the use o f  prescription drugs. The findings o f  the 
study show that individuals with more generous insurance coverage buy more 
prescription drugs but that the proportion o f  brand name drugs among all drugs purchased 
in pharm acies was not a function o f  insurance plan. This seems to make sense since 
health insurance covered the majority, if  not all, o f  the cost o f a prescription in 1985 and 
there were no concerns about steering people from a brand to a generic during that time 
period. Independent variables for the experiment included: insurance plan coinsurance, 
location o f  the individuals involved in the study and demographics o f  the individuals
18
(age, sex). D ependent variables included: the num ber o f  prescriptions per capita, 
percentage o f  drugs purchased through physicians and percentage o f  generic drugs 
purchased at pharmacies. This study provides im portance research for this thesis in that 
it tests w hether individuals w ith “less generous” insurance try to minimize their out-of- 
pocket expenses w hen purchasing prescription drugs.
Harris, Stergachis & Reid (1990), studied the effects o f  drug copaym ents on 
utilization and costs o f  pharmaceuticals in a Health M aintenance Organization. The data 
set consisted o f  a continuously enrolled cohort o f  HM O m em bers at Group Health 
Cooperative o f  Puget Sound (GHC). The independent variable (copayment) was 
com pared to the dependent variables: num ber o f prescription drugs dispensed, drug 
ingredient cost, average drug cost per prescription to the GHC and an evaluation o f 
therapeutic classes o f  drug utilization. Comparing variations in “essential” and “non- 
essential” utilization, the authors varied the copaym ent am ounts from $0 to $1.50 to 
$3.00 to $5.00 in an HMO to see the variation in costs and utilization. The results o f  the 
study indicate that cost sharing has a significant impact on reducing drug utilization and 
drug expenditures. “During the entire four-year follow -up period (including base-line), 
the copaym ent cohort experienced a reduction in drug use (-11% unadjusted) while drug 
use in the com parison cohort continued upward (+15% unadjusted)” (p.912). This study 
supports M otheral and Henderson’s economic theory that a copaym ent will reduce 
utilization.
Trying to answer the same question, Dean Smith (1993), evaluated the use and 
cost effect o f  prescription drug copaym ents. The null hypothesis o f  this study is that 
“variation in use and cost o f  prescription drugs is not associated with copayments or
19
incentives for generic substitution” (p. 192). The independent variable o f the study is 
copaym ent am ount and the dependent variables are: total cost per prescription, ingredient 
cost per prescription, dispensing cost per prescription, em ployer costs, and claims. The 
results o f  the study indicate that “higher copaym ent rates are associated w ith significantly 
low er num bers o f  prescriptions per person, and nearly offset higher ingredient costs per 
prescription” (p. 194). In addition, the presence o f  a generic drug option is associated 
with significantly lower total costs, which is due to the lower costs for generic 
ingredients. This study suggests “m arginal changes in copaym ent rates and incentives for 
use o f  generic drugs are not likely to affect either total drug costs or the trend in total 
drug costs in a m eaningful and continuous m anner” (p. 196). W hat the copaym ent does 
affect is the com position o f  total drug costs (a larger portion shifted from the health plan 
to the consumer), a decrease in the cost o f  the insurance for the em ployer and a 5% 
decrease in the num ber o f  prescriptions. Smith suggests additional ways o f  controlling 
prescription drug costs through the im plem entation o f drug utilization reviews, 
pharm acist incentives to offer generic drugs and changing dispensing fees as well as 
m ore direct actions aim ed at pharm aceutical manufacturers.
M otheral and H enderson (1999b), exam ined the effects o f  a copaym ent increase 
on several key m easures when a co-paym ent increase from $ 10 to $ 15 occurred for brand 
drugs. “The dependent variables w ere selected to assess the effect o f  a co-pay increase 
on 1) utilization and expenditure, 2) com pliance with chronic medications and 3) w hether 
the effect o f  the copay increase varied with the type o f  medication” (p. 1385). The 
independent variables were age, sex and chronic disease score, which was calculated for 
a specific period o f  time. This study found that “ an increase in brand co-pay from $10 to
20
$15 was associated w ith reduced brand utilization and expenditures, reduced overall 
expenditures and increased generic utilization without a reduction in continuation with 
chronic m edications” (p. 1392). These studies are important to this research because the 
ability to steer people to generic drugs can have major cost saving im plications without 
reducing utilization or compliance.
G eneric com panies fill only about 42 percent o f  all drug prescriptions in this 
country. This is surprising because the price disparity with brand name drugs is striking. 
The generic m arket share accounted for slightly less than $20 billion in drug sales in 
1999; the brand com pany sales accounted for more than $90 billion. Industry advocates 
claim  that i f  generic sales inched up to 52%, Am erican consum ers would save an 
estim ated $11 billion a year in drug costs (Hall, 2001). The question is how to get 
consum ers to switch from  a brand nam e drug to a generic drug. Copaym ents by 
them selves are probably not enough, and this raises the question o f  how a closed 
form ulary m ight help to reduce utilization o f  costly “non-essential” prescribed drugs? A 
closed formulary is a listing o f  drugs that a physician m ay prescribe (i.e., a list o f  drugs 
approved for use within a health care setting). The physician is requested or required to 
use only formulary drugs unless there is a valid medical reason to use non-formulary 
drugs (Knogstvedt, 2001).
M otheral and Henderson (1999a), addressed the question o f  the effects o f  closed 
formularies on prescription drug use and costs through the exam ination o f  pharm aceutical 
usage and spending w ithin a closed formulary. The objective o f  the study was to 
exam ine the effect o f  a closed form ulary on pharm aceutical use, expenditures, and 
treatm ent continuation in a general population o f  children and adults com pared to a
21
control group. Independent variables included formulary (vs. control group) m em ber age,
m em ber gender and CDC. Some o f  the dependent variables included 20 therapeutic
classes o f  drugs, generic fill rate, average cost per claim, total num ber o f  generic and
brand claim s, etc. The findings o f  the study show,
The num ber o f  people who had claims for prescription drugs decreased 
from the pre- to post-im plem entation period for the form ulary group and 
that the form ulary group experienced a decrease in total cost, brand cost, 
total claim s, brand claim s and generic claims, w hile the control group 
show ed an increase (p. 484).
The results o f  the data indicate that a closed formulary can result in substantial savings to
the payer, prim arily  due to a reduction in the use o f  brand m edications, as well as a
reduction in the utilization o f  discretionary drugs. In addition, their findings have
im plications for the design o f  future prescription drug benefits.
Looking beyond the prescription copay, Hillm an et al., (1999), published a study
exam ining financial incentives and drug spending in m anaged care. The purpose o f  the
study was to “exam ine not only the im pact o f  cost sharing on the am ount o f drug use but
also the im pact o f  the prices patients pay for a closely related service, the physician visit”
(p. 190). The independent variables included the type o f  m anaged care plan, prescription
drug copaym ent and physician office visit copaym ent. D ependent variables included
probability o f  claim s, am ount o f  spending for persons w ith at least one pharm aceutical
claim  and predicted am ount o f  spending on pharm aceuticals for all persons. The study
found that h igher copaym ents for physician visits, as well as h igher copaym ents for
prescription drugs, were associated with low er drug spending. The results o f  the study
indicate that high copaym ents w ere associated w ith low probability  o f  having any
pharm acy claim s. This result is expected, because the large copaym ent w ill absorb the
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entire cost o f  the prescribed m edication and elim inate the m anaged care organization’s 
claim s responsibility. In addition, the study found that physicians w ith low m otivation to 
curb drug spending, as in the IPA model o f  m anaged care, w ere m ore w illing to write 
prescriptions. Conversely, direct financial incentives for physicians to control drug use, 
as in the netw ork m odel o f  m anaged care, m ay have encouraged physicians to prescribe 
only essential drugs.
B reaking dow n the utilization o f  prescription drugs when a copaym ent is 
instituted, R eeder and Nelson (1985), studied the effect o f  copaym ents in the M edicaid 
population on several different therapeutic classes o f  drugs. The study produced 
surprising results, “copaym ents appear to exert a differential effect on the utilization o f 
drugs in various therapeutic categories” (p. 400). W hile the im position o f  a copaym ent 
had no apparent effect on the utilization o f  certain therapeutic classes (drugs used to 
control pain and sleep aids), the m ost shocking result was that individuals on 
cardiovascular drugs showed a reduction in utilization w ith the im plem entation o f  a co­
paym ent.
Dubois et al., (2000), exam ined price and volum e factors that influence the level 
of, and growth in, spending on prescription drugs. In answ ering the question, how much 
spending is driven by price rather than volum e, the results o f  the study indicate that 
“volum e, not price, is the largest driver o f  drug spending” (p. 231).
Separating pharm acy spending into price and utilization com ponents, Chem ew, 
Smith, K irking, and Fendrick (2001), observed that utilization, as opposed to price, was 
the prim ary determ inant o f  increased pharm aceutical expenditure in HM Os. R ising prices 
w ere not the prim ary driver o f  cost growth. “O ver the tw o-year study, price growth was
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relatively m odest, about 4%. Instead w hat drove expenditure increase was a dramatic 
shift in utilization patterns. A m ong HM O members, use o f  new  products contributed 
significantly to cost grow th, but use o f  core products also rose substantially” (p.672). 
One w ould expect new  products to be the m ost costly and drive prescription drug costs 
since they are patent protected and the demand for them w ill be greater than existing 
products due to their new ness to the market.
All o f  these studies are im portant for this thesis in that they m ay help to create a 
m ore cost-effective form ulary, or lead to a better designed copaym ent system  based on 
therapeutic class rather than a generic versus brand tiered copaym ent system.
This research is im portant to employers and the A m erican public because o f  
questions such as: A t w hat am ount does a copaym ent becom e a deterrent to the use o f 
prescription drugs? H ow  do prescription drug costs affect other health care services? 
H ow  do prescrip tion drug copaym ents affect the utilization o f  different therapeutic 
classes o f  m edications? All o f  these questions and m any others need to be researched 
and answ ered. W e do not w ant to create barriers that actually prevent care or act as a 
deterrent to an ind iv idual’s ability to obtain necessary, cost effective health  care service.
24
Hypotheses
The purpose o f  this study is to examine the effect that a change in prescription 
drug copaym ents has on drug costs and utilization. Understanding whether cost growth is 
attributable to changes in copaym ent levels, changes in prescription drug ingredient cost 
or changes in prescribing patterns and quantities, is essential to target efforts to contain 
expenditures. To statistically evaluate the effect o f  copayments, the following null 
hypotheses are considered in this study.
H o i: A $5.00 increase in prescription drug copayment will have no effect on 
overall utilization (num ber o f  prescriptions) o f  prescription drugs.
H0 2 : A $5.00 increase in prescription drug copayment will have no effect on the 
cost o f  the prescription drugs to the HMO.
25
Study Design
To em pirically exam ine the effect o f  prescription drug copaym ents on cost and 
utilization in the general population, a tim e series, cross-sectional, cohort study is used. 
This thesis study will com pare prescription drug cost and utilization changes resulting 
from  a pre and post prescription drug copay change. The sample was obtained from a 
network model M id-w est Health M aintenance Organization and includes a random 
sam ple o f  2,389 mem bers from one large em ployer group, which changed its prescription 
drug copaym ent from $0.00 in 1998 to $5.00 in 1999. Individual m em ber claims will be 
exam ined  on a p re and post drange basis for utilization and cost variations. The 
following variables have been selected to assess the effect o f a copaym ent on 1) 
utilization and 2) costs:
•  Total claims per m em ber per year
• Ingredient cost per member per year,
•  Fill fee per m em ber per >ear,
•  Add in fee per member per year,
•  HM O drug costs per m em ber per year,
•  Total drug costs per m em ber per year and,
•  Generic fill rate.
This research w ill address key questions including, “How does an increase in a 
prescription drug copaym ent affect cost and utilization?” “How does a copaym ent affect 
utilization am ong generic and brand drugs?”
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Population Demographics of Data
For an individual m em ber to be eligible for the study he/she m ust have been 
continuously enrolled in the plan from 1/1/98-12/31/99. From an overall population o f  
10,456 individuals, 2,389 individuals were found to have been continuously enrolled in 
the plan. A dem ographic breakdown o f  these 2,389 individuals by age and sex is 
presented below  in table 1.
Table 1: Characteristics o f Study Group
Age Number of Number of %
Range Males Females Total Individuals
0-5 109 76 185 7.7%
6-10 77 81 158 6.6%
11-15 100 103 203 8.5%
16-20 116 109 225 9.4%
21-25 77 65 142 5.9%
26-30 36 69 105 4.4%
31-35 70 73 143 6.0%
36-40 75 89 164 6.9%
41-45 82 108 190 8.0%
46-50 147 144 291 12.2%
51-55 151 144 295 12.3%
56-60 114 100 214 9.0%
61-65 48 26 74 3.1%
Total 1202 1187 2389 100.0%
% of Total 50.3% 49.7% 100%
Mean 33.6 33.64 33.62
SD 19.22 18.02 18.63
See figure 7 for histogram o f  the study sample.
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Operationally Defining the Variables
The following is an operational description o f  all the variables included in this
study.
Add-in-Fee- a discount paid to the HMO by the prescription drug manufacturers which 
may be based on volum e or utilization.
A ge- the age o f  the individual on January 1, 1998.
Brand Drug- the originator drug that receives the initial FDA patent and can not be 
reproduced by any other manufacturer while under patent. The FDA patent protection 
time is 17 years.
Copaym ent- a fee ($0 in 1998 and $5.00 in 1999) charged to every member o f  the HMO 
w hen a prescription drug is purchased.
Fill Fee- a dispensing fee charged by the pharm acy for filling prescriptions. The 
dispensing fee in 1998 through Novem ber 1999 was paid to pharmacies on a tiered 
incentive basis ranging from $2.50 per fill for those pharmacies with a generic dispensing 
rate o f less than 40%  to a m aximum dispensing fee o f $5.50 for pharmacies with a 
generic fill rate o f  greater than 65%. In N ovem ber 1999, the dispensing fee changed for 
generic prescriptions to $3.75 regardless o f  overall generic dispensing rates. The 
dispensing fee for brand-only medications becom e $2.50.
Generic Drug- a chem ically equivalent copy designed from a brand-nam e drug whose 
patent has expired. Typically less expensive and sold under the common name for the 
drug, rather than the brand name.
Generic Fill Rate- a ratio that describes the num ber o f  prescriptions filled with a generic 
drug versus a brand drug.
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HM O prescription drug costs- equals ingredient cost plus fill fee minus add in fee 
(rebate) minus copayment.
Ingredient Cost- the am ount paid to the pharmacy for a prescribed drug.
PM PY - abbreviation for per m em ber per year.
Total prescription drug costs- equals ingredient cost plus fill fee minus add in fee 
(rebate).
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Study Limitations
This study could be questioned on the basis o f  the sample, w hich is limited to one 
em ployer group who, over the years, has provided exceptionally high levels o f  benefits 
for all em ployees. Salary ranges for the individuals in this study are not necessarily 
representative o f  the average incom e o f  an individual living in the M idwest. A problem 
w ith the ability to generalize these findings to other em ployer groups m ay exist since 
ones ability to purchase drugs is a function o f  incom e and this variable is unknown.
Analysis of the Data
In order to test the statistical significance o f  the effects o f  a copaym ent I will be 
using difference-of-m eans Mests. The t-test is calculated using the standard formula:
( x i -  X 2 )
( ( a M - l )  +  ( a 2 / N 2 - i ) ) ' 5
w here Xj and X 2 are m eans for 1998 and 1999 variables (total claim s PM PY, brand 
claim s PM PY , generic claims PM PY, total drug costs PM PY, total generic costs PMPY, 
total brand costs PM PY, HM O total drug costs PM PY, HM O total generic costs PMPY, 
H M O  total brand drug costs PM PY), and Qjand o 2 are the standard deviations o f the
variables in each year, and Ni and N 2 represent the sample sizes in each year.
To assess statistical significance, the t-statistic generated from a difference-of- 
m eans test w ill be com pared to the critical value from a t-statistic table. The critical 
value for the 1% level o f  statistical significance is 2.576. Therefore, a t-statistic from a 
difference-of-m eans test m ust be greater than 2.576 to be considered statistically 
significant at the 1% level.
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Study Findings
Table 2: Difference of Means Analysis
Percent
1998 1999 Change
A. Utilization Analysis PMPY
Generic Drug Claims
Mean 5.92 5.04 -14.9%
Standard Dev. 9.45 8.59
Brand Drug Claims
Mean 5.56 5.86 5.4%
Standard Dev. 11.48 11.82
All Claims
Mean 11.48 10.90 -5.1%
Standard Dev. 16.71 16.32
B. Total Drug Cost Analysis PMPY
Generic Drug Cost
Mean $ 80.22 $ 80.23 0%
Standard Dev. $ 14.64 $ 16.69
Brand Drug Cost
Mean $ 317.93 $ 361.69 13.6%
Standard Dev. $ 77.84 $ 85.03
All Drug Cost
Mean $ 398.14 $ 445.50 11.9%
Standard Dev. $ 59.32 $ 67.22
C. HMO Total Drug Cost Analysis PMPY
Generic Cost
Mean $ 80.18 $ 59.37 -26.0%
Standard Dev. $ 14.64 $ 16.67
Brand Cost
Mean $ 317.74 $ 332.24 4.6%
Standard Dev. $ 77.82 $ 85.05
All Drug Cost
Mean $ 397.91 $ 391.61 -1.6%
Standard Dev. $ 59.32 $ 61.13
Difference in 
the Two Periods
(3.37)***
(0.89)
( 1.21 )
(0.02)
(18.38)***
(25.82)***
(45.84)***
(6.15)***
(3.44)***
*** indicates statistical significance at the 1% level, critical value = 2.576.
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Difference of Means Analysis (Con't)
Percent Difference in 
1998 1999 Change the Two Periods
D. Cost Component Analysis
Ingredient Cost PMPY
Mean $ 377.07 $ 427.06 13.3% (27.08)***
Standard Dev. $ 59.87 $ 67.49
Fill Fee PMPY
Mean $ 32.76 $ 32.06 -2.1% (17.15)***
Standard Dev. $ 1.42 $ 1.40
Add-In-Fee PMPY
Mean $ 11.80 $ 13.61 15.3% (16.90)***
Standard Dev. $ 3.61 $ 3.79
*** indicates statistical significance at the 1% level, critical value = 2.576.
Table 3: Generic Fill Rate, 1998 to 1999 
YEAR RATE
GENERIC FILL RATE 1998 51.6%
GENERIC FILL RATE 1999 46.2%
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Empirical Results
Table 2 displays the results o f  the difference-of-m eans analysis, which generally 
shows statistically significant changes in costs but not utilization as the driving factors for 
the changes in prescription drug expenditures for this health plan.
Panel A shows that generic prescription drug utilization decreased significantly 
from 5.92 prescriptions per m em ber per year (PM PY) in 1998 to 5.04 prescriptions 
PM PY  in 1999 (t-statistic o f  3.37 is significant at the 1% level). Brand drug and overall 
prescription drug utilization did not change significantly over the same period o f  tim e as 
the insignificant t-statistic indicates. Brand drug utilization increased from 5.56 
prescriptions PM PY  in 1998 to 5.86 prescriptions PM PY  in 1999 but the increase was not 
statistically significant. Likewise, overall prescription drug utilization decreased from 
11.48 prescriptions in 1998 to 10.90 in 1999 but the difference w as not statistically 
significant.
Panel B com pares the total drug cost PM PY from 1998 to 1999. The results in 
Panel B indicate that total drug costs for all prescription drugs, as w ell as for brand drugs, 
increase significantly (at the 1% level as the t-statistics indicate) but that generic drug 
cost did not significantly change. Total drug costs for generic drugs PM PY  increased 
from $80.22 in 1998 to $80.23 in 1999 but the difference is not statistically significant. 
Total drug costs for brand drugs PM PY  significantly increased from  $317.93 in 1998 to 
$361.69 in 1999 w ith a t-statistic o f  18.38 (significant at the 1% level). Total drug costs 
for all drugs PM PY  significantly increased from $398.14 in 1998 and $445.50 in 1999 
with a t-statistic o f  more than 25 (significant at the 1% level).
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In com parison, Table 2, Panel C com pares HM O total drug costs from 1998 to 
1999 for all drugs and shows that, generic drugs and brand drugs changed significantly. 
H M O  total drug costs for generic drugs PM PY significantly decreased (at the 1% level) 
from $80.18 in 1998 to $59.37 in 1999 as the t-statistic o f  45.84 indicates. HM O total 
drug costs for brand drugs PM PY increased significantly from  $317.74 in 1998 to 
$332.24 in 1999 w ith a t-statistic o f  6.15. HM O total drug costs for all drugs PMPY 
significantly decreased from $397.91 in 1998 to $391.61 in 1999 w ith a t-statistic o f  3.44.
Table 2, Panel D com pares the cost variables that com pose the total cost o f  
prescription drugs PM PY. Results indicate that all cost variables significantly changed. 
Ingredient cost PM PY  significantly increased from $377.07 in 1998 to $427.06 in 1999 
w ith a t-statistic o f  27.08 (significant at the 1% level). Fill fee PM PY significantly 
decreased from $32.76 in 1998 to $32.06 in 1999 w ith a t-statistic o f  17.15 (significant at 
the 1% level). A dd-in-fee PM PY  significantly increased from $11.80 in 1998 to $13.61 
in 1999 w ith a t-statistic o f  16.90.
Table 3 shows a decrease in the generic fill rate o f  51.6%  in 1998 to 46.2% in
1999.
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Discussion of Study Findings
Based on the analysis o f  the data and the em pirical results in Table 2, we can 
conclude that brand name drug costs, rather than overall utilization, or generic drug costs 
are the driving factors behind the rapidly rising costs o f  prescription drugs. The decrease 
in generic drug use is statistically significant, as shown in Table 2, Panel A, as well as an 
im portant concern to the HMO because o f  the im pact on costs. W hile generic drug 
utilization decreased 14.9%, total drug utilization only decreased 5.1% and was not 
statistically significant as shown in table 2, Panel A. The large decrease in generic 
utilization is offset by an increase in brand drug utilization o f  5.4%; however, the 
increase in brand utilization is not statistically significant. Overall, the prescription drug 
copaym ent benefit had no statistically significant effect on drug utilization.
One concern arising from these findings is that the percent o f  prescriptions filled 
with generic medication dropped from 51.6% in 1998 to 46.2%  in 1999 (see Table 3). I f  
the goal o f  the copay is to make consumers aware o f  the cost o f  their prescriptions, flat 
copaym ents did not accomplish this. Consumers seem to be making no distinction 
between generic drugs, which average $16.70 per claim and brand drugs, which average 
$61.66 per claim. In addition, the hypothesis that a population consumes more drugs as it 
ages is not supported by this study. This m ight be due to an increase in the prescription 
drug copaym ent from $0.00 to $5.00, which could have motivated individuals to ask for 
an increase in the supply o f  maintenance drugs. An increase o f  30 days to 60 days would 
increase prescription drug costs while reducing overall claims. This would also allow an 
individual to maximize the am ount o f  drugs received for a single copayment.
This shift in generic to brand utilization helps to explain the increase in total 
prescription drug expenditures as shown in Table 2, Panel B. Evaluating total drug costs,
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generic drugs did not show a statistically significant increase in the cost PM PY. The total 
cost PM PY  for generic drugs did not increase while the cost for brand drugs and total 
drug cost both had statistically significant increases. Total drug costs for brand drugs 
increased 13.6% and the total cost for all prescriptions increased 11.9% (see Table2, 
Panel B). The costs o f  brand drugs and the increase in the utilization o f  brand drugs, is 
driving the H M O ’s total prescription drug costs.
W hen considering the effects o f  an increase in prescription drug copaym ents we 
find that HM O  drug costs for all drugs decreased significantly after the introduction o f 
the copaym ent (table 2, panel C). The $5.00 copaym ent was associated with a significant 
decrease in generic drug cost by 26%  (significant at the 1% level) but brand drug costs 
significantly increased by 4.6%  after the copaym ent started (significant at the 1% level).
Looking in Table 2, Panel D, at the variables that com pose total drug costs, all 
had statistically significant changes (as the t-statistic indicates) after the introduction o f 
the copaym ent. Between 1998 and 1999, the ingredient costs for all prescription drugs 
PM PY  increased by 13.3% (significant at the 1% level), which can be explained by the 
increase in brand drug utilization. The fill fee PM PY  decreased significantly by 2.1%, 
w hich m ay have been caused by the new fill fee rates that took effect in N ovem ber 1999, 
as well as the change in the mix o f  drugs filled by the pharm acists. The add-in-fee 
PM PY  increased significantly by 15.3%, m ost likely again due to the increase in brand 
drug utilization, which helps offset the trem endous increase in ingredient costs.
Consum er cost-sharing has been a long-standing com ponent o f  pharm aceutical 
cost containm ent policy. Published m anaged care organization data clearly dem onstrate 
that higher copaym ents are associated with lower utilization and low er prescription drug
costs (Frendrick et al., 2001). In this study, the increase in copaym ent from $0 to S5 may 
not have been adequate to provide sufficient financial incentives to change utilization 
habits.
In order to lower total prescription drug costs as well as HMO drug costs, 
switching from a flat copaym ent to a two tier copayment system ($5 for generic and 
$10 for brand) could help steer people away from costly brand drugs to generic drugs.
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Future Ways to Decrease Cost and Utilization
Copaym ents do not reduce the average cost per prescription drug; they simply
pass som e o f  the cost on to the consumer. In order to decrease prescription drug costs,
society m ight consider im plem enting the following: 3 tier co-paym ent systems, where the
m ost cost effective drug is the cheapest to purchase, closed form ularies, which will
elim inate the prescribing o f  certain drugs, and other creative organizational controls that
lim it the utilization o f  expensive non-cost effective drugs but also ensure that individuals
w ho need prescription drugs have affordable access to them. Figure 8 shows that in
1999-2000, approxim ately 40%  o f  the increase in prescription drug spending was caused
by an increase in the num ber o f  prescriptions, and that over 50% o f  the increases were
caused by factors such as drug price increase and a shift to higher cost drugs (DBT,
2001). This is w hy we need to find ways to steer individuals to drugs that are both
beneficial and cost effective. Changing utilization patterns alone w ill not help to control
the expenditures on prescription drugs for very long.
Frendrick, Smith, Chem ew , and Shah (2001), suggest a new concept called the
Benefit-Based Copay (BBC), w hich builds on the fundam ental concept o f  all drug benefit
plans in its desire to provide basic pharm aceutical coverage:
W hat distinguishes BBC from  existing systems is its determ ination o f  the 
patien t’s copay based on m edical need and costs, as best determ ined from 
the available m edical and econom ic evidence. In the BBC, a patien t’s 
copay is based on the expected clinical benefit from the prescribed drug.
The BBC allows the copay to vary by the evidence-based benefit o f  the 
m edication for the individual patient (p. 862).
In order to reduce the utilization o f  costly brand nam e drugs, the ability to increase brand 
to generic ratios needs to be further studied and improved. This issue needs to be studied 
and understood in order to reduce utilization o f  costly m edications.
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In addition to increasing prescription copaym ents, other variables such as 
im plem enting better m edical practices, educating the A m erican public as well as 
physicians, and using the H ealth and Lifestyle departm ents in m anaged care 
organizations need to be exam ined in order to evaluate their effect on lowering 
prescription drug utilization. “I f  volum e represents the prim ary driving force behind drug 
spending growth, then future research should exam ine this volum e and determ ine what 
use is appropriate and w hat use is not. But this exam ination m ust also focus on the 
im pact o f  m edications on the total cost o f  care and the overall im provem ent in the 
patients’ w ell-being” (D ubois et al, 2000). I f  the increase in the am ount o f  m oney spent 
on prescription drugs helps to reduce other health care expenses, such as inpatient 
hospitalization, then the additional prescription expenditures should be viewed as both 
beneficial and an overall cost effective m eans o f  reducing national health care costs.
The question is, “How do we increase the educational levels o f  the Am erican 
public?” U sing services such as disease m anagem ent program s can help create healthier 
lifestyles and a reduction in prescribed drugs. Increased health  education m ay also 
reduce utilization o f  several therapeutic classes o f  m edications such as LD L inhibitors. A 
better, healthier diet can reduce LD L levels, and possibly elim inate the need for high 
blood pressure m edications. Educating physicians on the costs o f  prescription drugs and 
some o f  the alternative, cost-effective treatm ents that are available, m ay reduce costs 
w ithout affecting utilization.
Roth, Plastaras, M ullin, Fillm ore and M oses (2001), studied the effect that 
educational intervention had on selected expensive m edications. The study results 
showed that “substantial decreases in the prescribing o f  certain expensive m edications
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can be attained by substituting less costly medications: this can be accom plished through 
a simple and cost-effective educational and reminder program ” (p. 636). Having HMOs 
im plem ent some type o f  physician education program  to inform physicians o f  the costs 
associated w ith certain prescription drugs could have a trem endous effect on decreasing 
prescription drug costs.
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Conclusions
Im plications for M anaged Care
The purpose o f  this study was to see w hat effect, i f  any, an increase in 
prescription drug copaym ents would have on utilization and associated costs. Smith and 
K irk ing’s (1992) review o f the available studies on the relationship between consum er 
fees and drug utilization suggests that, “the dem ands for drugs tends to be insensitive to 
consum er fees. Even incom e and health needs, two factors that are im portant 
determ inants o f  the dem and for other goods and services, are not generally significant for 
drugs, w ithin the scope o f  research on insured populations” (p. 340). The fact that 
utilization did not significantly change when a $5 copaym ent was added is supported by 
these other studies.
Costs paid by the HM O were significantly reduced by 1.2% from 1998 to 1999 
after the im plem entation o f  a $5 copay; however, total drug costs increased nearly 12% 
due to the increase in the num ber o f  prescriptions filled w ith brand drugs rather than 
generic. The im plem entation o f  a copaym ent sim ply shifted part o f  the econom ic burden 
from  the em ployer and HM O to the consumer.
Em ployers, armed w ith the know ledge that they can offset prem ium  costs by 
im plem enting prescription drug copaym ents, w ill be able to pass on any costs they feel 
they cannot absorb w ithout causing the quality o f  their em ployee’s health care to 
dim inish. This phenom enon is currently occurring throughout the country. Em ployer 
sponsored healthcare plans are being forced to raise prescription copaym ent levels to 
protect them selves from the double-digit prem ium  increases that insurance com panies say 
they need in order to keep up w ith m edical expenses.
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M anaged care organizations can benefit from this study by realizing that a flat 
copaym ent does not steer people away from costly brand nam e drugs, and that 
im plem enting a tw o-tier copaym ent systems could possibly help control utilization o f 
these drugs.
I f  we expect to enjoy continuing prescription drug coverage through our 
em ployers, we need to find ways to control spending, especially when health care 
expenses continue to skyrocket for both em ployers and m anaged care organizations. 
Cost sharing for prescription drugs seems to be a logical step in m aking the consum er 
aw are o f  the trem endous expense associated w ith the benefit. The only deterrent to cost 
sharing w ould be i f  em ployers and insurers cross the invisible econom ic line that causes a 
decrease in prescription drug utilization but an increase in other health care expenses, 
such as em ergency room  visits.
Im plications for Public Policy
In the upcom ing months, the debate in congress over a national prescription drug 
program  will continue to escalate. Com pounding this issue is the fact that M edicare will 
have to w ithstand the retirem ent o f  70 m illion new ly eligible baby boom ers in the next 10 
years, and still lacks an outpatient prescription drug benefit. All o f  this is taking place as 
prescription drug costs and utilization continue to escalate dram atically (Rovner, 2001).
M edicare attem pts to deliver quality health care. A ccording G inzberg (1990), this 
im plies that an individual w ill have adequate insurance coverage to pay for the range o f 
services that a physician believes w ill contribute optim ally to the individual's recovery 
w ithout exposing him /her to undue risk. W ithout outpatient prescription drug benefits,
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M edicare recipients, most o f  whom live on fixed incomes, must choose between 
purchasing essential drugs to m aintain their health or paying other necessary bills such as 
grocery  or heating.
I believe that this research can be transferred from the private insurance 
marketplace to a government-sponsored national prescription drug program. The 
governm ent has m any options available when considering the addition o f  an outpatient 
prescription drug program , whether it is a stand alone program or an attachm ent to the 
M edicare program. As this study concludes, a nominal copayment can help offset 
prescription drug costs for the insurance provider w ithout negatively affecting utilization 
and the quality o f  care.
Through this study and others that were reviewed in the literature, offering the 
following benefit options would help to control government expenditures in a national 
prescription drug program  and reduce the current out-of-pocket expenditures presently 
absorbed by individuals currently covered under Medicare.
•  Limiting the formulary: By offering a combination o f  generic only or the 
m ost cost effective treatm ent options, the government would institute a cost control 
m easure which could help to lim it exposure to the costliest drugs. I f  individuals want a 
drug not on the formulary, they can pay for the difference in the cost o f  the drug 
themselves. This is still better coverage than they currently receive.
• Im plem enting fixed or percent copaym ents for all prescription drugs 
covered under the plan would also help to insulate the government from the rise in 
prescription drug costs while offsetting some o f the initial cost o f a prescription. I 
recom m end a percent copaym ent because this would protect the government from
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inflation as well as the rising costs that pharm aceutical com panies incur in the production 
o f  drugs (advertising, etc).
A national prescription drug benefit program  for M edicare recipients w ould have 
several potential benefits. One such benefit is that outpatient drug coverage could also 
reduce unnecessary expenditures in other health care areas such as em ergency room 
utilization, w hile freeing up m onies to pay for other necessary expenditures. A nother is 
that an individual would be receiving the com plete health care benefits recom m ended by 
their physician.
I f  the governm ent is to successfully institute a national prescription drug program, 
lim iting the benefits through copaym ents and reducing the num ber o f  prescription drugs 
on the form ulary would be a great w ay to help the program  in its initial developmental 
phases. A copaym ent o f  any am ount and a reduced form ulary could help to offset costs 
for individuals on M edicare w hile providing better coverage and m ore com prehensive 
benefits than they currently receive. It w ould also protect the governm ent from 
trem endous increases in unnecessary annual expenses, caused by over utilization o f  the 
costliest drugs.
These cost-sharing provisions w ill not help to reduce the am ount necessary to set 
up the program , but some program  seem s inevitable, especially in light o f  projected drug 
costs for the country’s aging population. W ith new drug developm ents on the increase, 
the governm ent needs to find a w ay to m ake it possible for citizens to purchase the drugs 
necessary to m aintain their health w hile not causing an undue burden on their wallets.
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